Abiomed's Impella(R) Technology Showcased At ACC 2013

DANVERS, Mass., March 7, 2013 (GLOBE NEWSWIRE) -- Abiomed Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, notes that there will be over 15 Impella presentations in the scientific sessions at the annual American College of Cardiology (ACC) 2013 scientific meeting, scheduled from March 9 - 11, at the Moscone Convention Center in San Francisco.

On the ACC show floor, Abiomed will conduct daily booth demonstrations at Abiomed booth #N6 - 233 and hands-on simulations of the Impella platform.

For further information about the ACC program related to Impella and the timing of scientific presentations, please contact Aimee Genzler, Corporate Communications Manager, at agenzler@abiomed.com or 978-646-1553.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com.

The Abiomed logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13564

FORWARD-LOOKING STATEMENTS

This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K and most recently filed Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.
CONTACT: For further information please contact:         Aimee Genzler         Corporate Communications Manager         978-646-1553         agenzler@abiomed.com                  Susie Lisa         Senior Director, Investor Relations, Corporate Development         978-646-1590         slisa@abiomed.com

Abiomed Logo

If you liked this article you might like

FANG Stocks Only Outperform in Odd Years: Here Are 18 Alternative Picks for 2018

FANG Stocks Only Outperform in Odd Years: Here Are 18 Alternative Picks for 2018

Closing the Door on Abiomed

Closing the Door on Abiomed

Capturing Profits on AIG

Capturing Profits on AIG

A Roundup of My Open Positions

A Roundup of My Open Positions

Pumped Up About Abiomed Collar Play

Pumped Up About Abiomed Collar Play